Bulls Pile Into Moderna As FDA Decision Nears, Ignites 60% Surge In This ETF - Moderna (NASDAQ:MRNA), Def

Moderna surged about 60% over five trading sessions, lifting its market cap by roughly $6.2 billion to around $24 billion, according to Trefis. The rally followed the FDA releasing briefing documents ahead of a VRBPAC meeting on mRNA-based seasonal flu vaccine mFlusiva, which presented a largely balanced view despite evidence gaps in older and immunocompromised populations. The documents noted no major deficiencies and described potential product launches as promising, including a flu/COVID combination and a norovirus vaccine anticipated for 2027–2028 if approved. Moderna also reorganized and named Ester Banque as chief commercial officer, signaling a broader push into commercial-scale vaccine development alongside existing COVID-19 products.